<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357214</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR052322</org_study_id>
    <secondary_id>R01AR052322</secondary_id>
    <nct_id>NCT00357214</nct_id>
  </id_info>
  <brief_title>Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults</brief_title>
  <official_title>Effect of Potassium Bicarbonate on Bone and Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing evidence that the acid-base balance of diet plays an important role in&#xD;
      the health of bones and muscles. An excess of acid in the body can result in calcium loss and&#xD;
      muscle breakdown. Potassium bicarbonate, a base supplement, can neutralize acid within the&#xD;
      body. The purpose of this study is to determine the effectiveness of potassium and&#xD;
      bicarbonate, alone and combined, at reducing bone loss and preventing muscle wasting in older&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The typical American diet of dairy products, grains, and meats results in excess acid&#xD;
      build-up in the body. The kidney is often unable to remove this excess acid quickly enough,&#xD;
      resulting in mildly elevated blood acidity. In an attempt to neutralize the acidity, the body&#xD;
      releases calcium from its bones. Over time, however, this calcium loss can lead to decreased&#xD;
      bone density and possibly osteoporosis. Excess acid in the body also stimulates the breakdown&#xD;
      of muscle. The combination of osteoporosis and reduced muscle strength sets the stage for&#xD;
      falls, fractures, and ultimately functional decline. At least 30% of older adults fall once a&#xD;
      year and, of those falls, 5% result in fractures. Preserving muscle mass and strength is an&#xD;
      effective way to lower the risk of falling and to maintain independence among older people.&#xD;
      Potassium bicarbonate is a base supplement that can neutralize acid. The purpose of this&#xD;
      study is to determine the effectiveness of potassium and bicarbonate, alone and combined, at&#xD;
      reducing bone loss and preventing muscle wasting in older adults.&#xD;
&#xD;
      This study will last 3 months. Participants will be randomly assigned to one of four&#xD;
      treatment groups:&#xD;
&#xD;
        -  Group 1 will receive potassium bicarbonate supplements&#xD;
&#xD;
        -  Group 2 will receive potassium chloride supplements&#xD;
&#xD;
        -  Group 3 will receive sodium bicarbonate supplements&#xD;
&#xD;
        -  Group 4 will receive placebo supplements&#xD;
&#xD;
      All participants will take three pills of their assigned supplement after each meal; this&#xD;
      will occur on a daily basis throughout the study. Participants will also take a multivitamin&#xD;
      and a 600-mg calcium tablet daily. Participants will not be required to alter their usual&#xD;
      diet in any way, but they will be requested to not take their usual calcium and vitamin D&#xD;
      supplements during the study. Study visits will occur on Days 1, 21, 49, and 84. Days 1 and&#xD;
      84 study visits will include a review of medical history and physical activity, blood&#xD;
      collection, and evaluation of weight, blood pressure, calcium absorption, and muscle&#xD;
      function. Collection of both a 24-hour urine sample and a calendar depicting compliance with&#xD;
      the supplement schedule will also occur at these two visits. The other study visits, on Days&#xD;
      21 and 49, may include blood collection, calendar compliance checking, and weight and blood&#xD;
      pressure measurements. Supplements will be handed out on Days 1, 21, and 49.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Markers of Bone Turnover</measure>
    <time_frame>3 month change in 24-hr urine values</time_frame>
    <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>potassium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Bicarbonate</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>potassium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Chloride</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>Potassium chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo (microcrystalline cellulose)</intervention_name>
    <description>Given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass idex less than 35&#xD;
&#xD;
          -  Not currently on a weight gain or weight loss diet&#xD;
&#xD;
          -  Willing to maintain usual level of physical activity&#xD;
&#xD;
          -  Willing to refrain from taking own calcium supplements, antacids, or salt substitutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vegetarian&#xD;
&#xD;
          -  Use of glucocorticoids for more than 10 days in the 3 months prior to study entry&#xD;
&#xD;
          -  Use of estrogen, raloxifene, or calcitonin in the 6 months prior to study entry&#xD;
&#xD;
          -  Use of bisphosphonate or teriparatide in the 2 years prior to study entry&#xD;
&#xD;
          -  Current use of diuretics, nonsteroidal anti-inflammatory drugs (NSAIDS),&#xD;
             beta-blockers, anabolic drugs (steroids or other), angiotensin converting enzyme (ACE)&#xD;
             inhibitors, or angiotensin receptor blockers (ARBs)&#xD;
&#xD;
          -  Renal disease, including kidney stones in the 5 years prior to study entry or&#xD;
             creatinine clearance less than 50 ml/min/1.73 m2 of body surface area&#xD;
&#xD;
          -  Hyperparathyroidism&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Significant immune disorder&#xD;
&#xD;
          -  Current unstable heart disease&#xD;
&#xD;
          -  Active malignancy or cancer therapy in the year prior to study entry&#xD;
&#xD;
          -  24-hour urine calcium levels greater than 300 mg/d after 1 week of being off calcium&#xD;
             supplements&#xD;
&#xD;
          -  Hypertension, congestive heart failure, arrythmias, or myocardial infarction in the 12&#xD;
             months prior to study entry&#xD;
&#xD;
          -  On a salt-restricted diet&#xD;
&#xD;
          -  Bone density total hip T score of less than -2.5&#xD;
&#xD;
          -  Abnormal serum calcium&#xD;
&#xD;
          -  Alkaline phosphatase levels greater than 10% above the upper end of the reference&#xD;
             range&#xD;
&#xD;
          -  Adrenal insufficiency, primary aldosteronism, or Bartter's syndrome&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Alcohol use exceeding two drinks/day&#xD;
&#xD;
          -  Peptic ulcers or esophageal stricture&#xD;
&#xD;
          -  Screening serum 25(OH)D levels below 16 ng/ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dawson-Hughes B, Harris SS, Palermo NJ, Castaneda-Sceppa C, Rasmussen HM, Dallal GE. Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women. J Clin Endocrinol Metab. 2009 Jan;94(1):96-102. doi: 10.1210/jc.2008-1662. Epub 2008 Oct 21.</citation>
    <PMID>18940881</PMID>
  </results_reference>
  <results_reference>
    <citation>Dawson-Hughes B, Castaneda-Sceppa C, Harris SS, Palermo NJ, Cloutier G, Ceglia L, Dallal GE. Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women. Osteoporos Int. 2010 Jul;21(7):1171-9. doi: 10.1007/s00198-009-1049-0. Epub 2009 Sep 1.</citation>
    <PMID>19727904</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <results_first_submitted>September 18, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Bess Dawson-Hughes</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>bone turnover</keyword>
  <keyword>calcium excretion</keyword>
  <keyword>nitrogen excretion</keyword>
  <keyword>potassium bicarbonate</keyword>
  <keyword>muscle loss</keyword>
  <keyword>muscle atrophy</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.&#xD;
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.&#xD;
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>participant age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="7.6"/>
                    <measurement group_id="B2" value="62.6" spread="7.6"/>
                    <measurement group_id="B3" value="63.4" spread="7.7"/>
                    <measurement group_id="B4" value="63.3" spread="7.7"/>
                    <measurement group_id="B5" value="62.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Markers of Bone Turnover</title>
        <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
        <time_frame>3 month change in 24-hr urine values</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate</title>
            <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Sodium Bicarbonate</title>
            <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Potassium Chloride</title>
            <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O4">
            <title>Microcrystalline Cellulose</title>
            <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.&#xD;
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Bone Turnover</title>
          <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
          <units>nmol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="1.75"/>
                    <measurement group_id="O2" value="-3.36" spread="1.68"/>
                    <measurement group_id="O3" value="-0.14" spread="1.71"/>
                    <measurement group_id="O4" value="0.5" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.&#xD;
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.&#xD;
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bess Dawson-Hughes</name_or_title>
      <organization>Tufts University</organization>
      <phone>617 556 3066 ext 6175100519</phone>
      <email>bess.dawson-hughes@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

